Narrow search
Showing 1 - 10 of 401
Cover Image
The Unaccounted Insurance Value of Medical Innovation
Subramaniam, Anushree - 2016
Traditional value of medical innovation models estimate the benefits of a new treatment to individuals who fall sick ex-post. However, economic theory suggests medical innovation has additional benefits ex-ante - before susceptible individuals know whether or not they will fall sick. This paper...
Persistent link: https://www.econbiz.de/10012993523
Cover Image
The Medicare Innovation Subsidy
Lemley, Mark A. - 2020
Policymakers on both ends of the political spectrum have been looking for ways to reduce prescription drug prices. Democrats have also been working on expanding healthcare coverage, including different versions of Medicare for All. All these proposals have been framed as issues of access and...
Persistent link: https://www.econbiz.de/10012848087
Cover Image
Patent Buy-Outs for Global Disease Innovations for Low- and Middle-Income Countries
Outterson, Kevin - 2014
Drug prices are uniquely susceptible to radical price reductions through generic competition. Patented pharmaceuticals may be priced at more than 30 times the marginal cost of production; the excess is the patent rent collected by the drug company while the patent and exclusive marketing periods...
Persistent link: https://www.econbiz.de/10014060277
Cover Image
The Vanishing Public Domain : Antibiotic Resistance, Pharmaceutical Innovation and Global Public Health
Outterson, Kevin - 2014
Penicillin and other antibiotics were the original wonder drugs and laid the foundation of the modern pharmaceutical industry. Human health significantly improved with the introduction of antibiotics. By 1967, the US Surgeon General declared victory over infectious diseases in the US. But pride...
Persistent link: https://www.econbiz.de/10014060278
Cover Image
Pharmaceutical Arbitrage : Balancing Access and Innovation in International Prescription Drug Markets
Outterson, Kevin - 2014
While neoclassical economic theory suggests that arbitrage will undermine global differential pricing of pharmaceuticals, the empirical results are more complex. Pharmaceutical regulation, IP laws, global trade agreements, and company policies support differential pricing despite the pressure of...
Persistent link: https://www.econbiz.de/10014070573
Cover Image
Valuing Medical Innovation
Hemel, Daniel J.; Ouellette, Lisa Larrimore - 2022
Scholars and policymakers across the ideological spectrum agree that the U.S. drug pricing system is deeply flawed. Most reform proposals focus on one symptom: high prices for existing drugs. But high prices aren’t all that ails the U.S. drug pricing system: Current law also provides weak...
Persistent link: https://www.econbiz.de/10014078244
Cover Image
Pharmaceutical M&A activity : effects on prices, innovation, and competition
Richman, Barak; Mitchell, Will; Vidal, Elena; Schulman, … - 2017
The rise of blockbuster pharmaceutical acquisitions has prompted fears that unprecedented market concentration will weaken competition. Two of the most prominent concerns focus on the upstream and downstream ends of the pharmaceutical industry: (1) the concern that these mergers will concentrate...
Persistent link: https://www.econbiz.de/10011721586
Cover Image
Is it Possible to Have Cheaper Drugs and Preserve the Incentive to Innovate? The Benefits of Privatizing the Drug Approval Process
Sauer, Corinne; Sauer, Robert M. - 2015
In this paper, we argue that lower prices for pharmaceuticals can be achieved by fostering a new type of competition in the pharmaceutical industry. Lower drug development costs, and hence prices, can be brought about by abolishing national drug administrations and replacing them with private...
Persistent link: https://www.econbiz.de/10014060120
Cover Image
Is It Possible to Have Cheaper Drugs and Preserve the Incentive to Innovate: Reforming the Drug Approval Process According to Market Principles
Sauer, Corinne; Sauer, Robert - Jerusalem Institute for Market Studies (JIMS) - 2005
, obtained through price control legislation and legislation that eases the entry of generic products into the market, has caused …
Persistent link: https://www.econbiz.de/10004995401
Cover Image
The impact of regional and functional integration on the post-entry performance of knowledge intensive business service firms
Koch, Andreas; Strotmann, Harald - 2004
the firms’ post-entry development. Nevertheless, few existing studies are dealing with questions of entrepreneurship in … the KIBS sector using micro firm data. This contribution gives an empirical analysis of the determinants of post-entry …-Classification: D21, J23, L80, O30 Keywords: Employment growth; Entrepreneurship; Entry; Innovation; Knowledge-intensive business …
Persistent link: https://www.econbiz.de/10011318984